Cerdulatinib

Cerdulatinib
Clinical data
Other names	PRT062070, PRT2070, DMVT-502
Routes of; administration	By mouth
Identifiers
	IUPAC name 4-(Cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide;
CAS Number	1198300-79-6 [PubChem];
PubChem CID	44595079;
ChemSpider	32822046 ;
UNII	D1LXQ45S1O;
CompTox Dashboard (EPA)	DTXSID001115521 ;
Chemical and physical data
Formula	C20H27N7O3S
Molar mass	445.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N;
	InChI InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25) ; Key:BGLPECHZZQDNCD-UHFFFAOYSA-N;

Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.

It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).

Clinical data

Other names	PRT062070, PRT2070, DMVT-502
Routes of administration	By mouth
Identifiers
IUPAC name 4-(Cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
CAS Number	1198300-79-6^Y[PubChem]
PubChem CID	44595079
ChemSpider	32822046^Y
UNII	D1LXQ45S1O
CompTox Dashboard (EPA)	DTXSID001115521
Chemical and physical data
Formula	C₂₀H₂₇N₇O₃S
Molar mass	445.54 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
InChI InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)^Y Key:BGLPECHZZQDNCD-UHFFFAOYSA-N